(24 Nov. 2021) Amgen Korea (GM: Sang Noh) announced it hosted the 1st Amgen-KAST Biotechnology Award 2021 at 5pm on Tuesday, 23 November with The Korean Academy of Science and Technology or KAST (President: Min-koo Han) in the KAST main auditorium.
This year marks the first Amgen-KAST Biotechnology Award which was established to discover and reward young scientists in Korea with a strong presence in basic life science and bio engineering research. Sponsored by the global biotechnology leader Amgen Korea and hosted by the most prestigious local academic association KAST, the award is given to selected 1 next-gen scientist and 1 postdoctoral researcher who have contributed to taking Korea’s biotechnology and research competitiveness to the next level through impressive research achievements.
This year Prof. Suk-yeon Hwang, School of Chemical and Biological Engineering, Seoul National University, and Se-jin Jeon, Ph.D, the Research Center for Cellular Homeostasis, Ewha Womans University, each won the award in the next-gen scientist category and postdoctoral researcher category. The winners were granted, along with the award plaque, the total prize money of 60 million won, 40 million and 20 million respectively.
Prof. Hwang, who won the next-gen scientist category, was recognized for his contribution to the advancements in life science in Korea with the development of new tissue regeneration and treatment using bioactive biopolymers and stem cells. More recent research works include manufacturing of new enzyme-based hydrogel which is in a preclinical stage for commercial use; and he was not just appreciated for his excellent research footprint in life science and biotechnology with around 110 books and research papers so far but also for his dedication to volunteering for proliferation and sharing of science culture and knowledge. Jeon, who won the postdoctoral researcher category, was recognized for the accomplishments in research on vascular diseases triggered by blood vessel and immune cell interactions. Unraveling the function and molecular mechanism of Ninjurin-1, a new anti-inflammatory cytokine in arteriosclerosis, her research was especially appreciated for suggesting factors in the human body as a therapeutic candidate for homeostasis and recovery of vascular diseases, not inhibition of previously-known stimulating factors of vascular diseases.
Sang Noh, GM, Amgen Korea, said: “The Amgen-KAST Biotechnology Award is an exciting opportunity for us to give more down-to-earth support to young dedicated researchers and scientists in Korea with unwavering passion for life science and biotechnology research. Results from tireless research and endeavor by dedicated promising scientific minds in Korea will be soon translated into developments in the domestic biotechnology sector. A basic science-powered biotechnology leader bringing transformative therapies to the world, Amgen Korea has many other initiatives in place than the Amgen-KAST Biotechnology Award that are designed to contribute to developments in basic science in Korea, including the Grow up, Bio up campaign advocating life science-learning for local children and adolescents. Amgen Korea will remain committed to fostering promising next-generation scientists and researchers and offering support measures to play our part in developments in the domestic life science sector.“
Min-koo Han, President, KAST, said: “I am truly happy and excited to discover and inspire young scientists who will be Korea’s future in life science, together with the biotechnology leader Amgen Korea. As the time calls for even more support and encouragement for young scientists and postdoctoral researchers, what makes the award even more meaningful is that it can help scientific and technical minds feel more proud of themselves and their works, and celebrate their research accomplishments. KAST will continue to spare no effort to help young scientists focus only on their work as they are the ones who will take the life science sector in Korea to the next level.”
A biotechnology leader dedicated to disease and therapeutic research by unlocking the potential of biology and basic science, Amgen Korea has been committed to developments in the domestic life science sector and building a stronger foundation for science culture through programs like the Amgen-KAST Biotechnology Award and the Grow up, Bio up campaign with the Seoul Science Center furthering science education for the next generations in Korea.
# # #
This media release was prepared to provide information on Amgen’s general business activities. Please take care not to risk potential violation of laws and regulations related to pharmaceutical advertising when referring to information contained in the media release.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com.
About Amgen Korea
Amgen Korea was established in November 2015 to further develop Amgen’s clinical pipeline which offers a wide range of products for bone disease, cardiovascular, oncology/hematology, nephrology, inflammation, neuroscience treatment and biosimilars, as well as to provide innovative medicines to patients in Korea who are suffering from severe diseases. As a member of the biotechnical industry, Amgen Korea will continue to contribute to the development of the Korean pharmaceutical industry by carrying forward diversified and positive activities.
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation.
We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful.
A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
Min-Jung Jung (firstname.lastname@example.org)
Mikyung Shin (email@example.com)
# # #